塞特梅拉诺提德可以成为获得的下丘脑肥胖症的游戏改变者吗?
Hanneke M van Santen1,2, Christian Denzer3, Hermann Lothar Müller4
1Department of Pediatric Endocrinology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Frontiers in endocrinology
|January 19, 2024
概括
塞特梅拉诺提德在治疗儿童获得的下丘脑肥胖症方面表现有前途,为治疗有效治疗方法有限的疾病提供潜在的缓解. 这种向治疗可以显著改善患者的治疗结果和生活质量.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 肥胖医学 肥胖医学
- 神经内分泌学神经内分泌学
背景情况:
- 在儿童中获得的下丘脑肥胖症,通常是喉瘤手术等治疗的结果,具有严重的风险,包括代谢综合征和过早死亡.
- 目前用于获得的下丘脑肥胖症的治疗方法取得了令人失望的结果,一些干预措施显示出相互矛盾的有效性.
- 黑色皮质素-4受体 (MC4R) 途径对于调节食欲至关重要;其干扰导致过食和下丘脑肥胖.
研究的目的:
- 评估MC4Ragonistsetmelanotide作为儿童患者获得的下丘脑肥胖症的向治疗的潜力.
- 讨论正在进行的前性,随机化,盲目的试验,调查setmelanotide对获得的下丘脑肥胖症.
- 考虑将setmelanotide分类为一种肥胖药物或下丘脑替代疗法.
主要方法:
- 在14名患有获得的下丘脑肥胖症的儿科患者中对setmelanotide治疗的初步结果的审查.
- 对计划进行为期12个月的前性随机盲目试验的设计和招聘进行讨论.
- 分析MC4R激素在治疗下丘脑功能障碍方面的潜在作用.
主要成果:
- 初步数据表明,setmelanotide治疗在患有获得的下丘脑肥胖症的儿科患者中是有前途的.
- 塞特梅拉诺提德在基因形式的下丘脑肥胖症中表现出显著的积极影响,患者的证词强调了改变生活的影响.
- 美国食品和药物管理局建议进行12个月的严格试验,以进一步评估疗效和安全性.
结论:
- 塞特梅拉诺提德代表了治疗获得的下丘脑肥胖症的潜在游戏改变者,这是一个历史上治疗选择不佳的疾病.
- 通过精心设计的临床试验进行进一步的研究是有必要的,以确认setmelanotide的疗效和安全性.
- 塞特梅拉诺提德可能提供一种新的方法,可能是作为下丘脑替代疗法,用于患有下丘脑肥胖症的儿童.
相关概念视频
01:30Regulation of Food Intake
233
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
233
01:24Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
01:15Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
01:27Major Hormones and Their Functions
396
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
396